PSNLHealthcare · Diagnostics & ResearchThe 5 Wall Street analysts covering Personalis, Inc. hold a median 12-month price target of $16 — -3.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 2 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Personalis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (95): The shares have been drifting up relative to others.
Volatility (14): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PSNL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −3.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | BTIG | Maintains | Buy | — |
| 20 July 2026 | BTIG | Maintains | Buy | $11 → $16 |
| 20 July 2026 | Lake Street | Downgrade | Hold | $16 |
| 20 July 2026 | Lake Street | Downgrade | Hold | — |
| 20 July 2026 | Needham | Downgrade | Hold | — |
| 20 July 2026 | Needham | Downgrade | Hold | — |
| 17 July 2026 | Needham | Maintains | Buy | $12 → $17 |
| 17 July 2026 | Needham | Maintains | Buy | — |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 11 May 2026 | BTIG | Maintains | Buy | — |
| 5 Mar 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 27 Feb 2026 | Needham | Maintains | Buy | — |
| 11 Feb 2026 | BTIG | Maintains | Buy | — |
| 26 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 9 Jan 2026 | BTIG | Reiterates | Buy | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 11 Nov 2025 | BTIG | Maintains | Buy | — |
| 11 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 11 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PSNL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Personalis, Inc. returned +247.0% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 8% of US stocks
Cheaper than 13% of US stocks
Cheaper than 87% of US stocks
Higher than 78% of US stocks
Higher than 23% of US stocks
Higher than 12% of US stocks
Higher than 4% of US stocks
Higher than 21% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Personalis, Inc. has a market value of $1.8B and an enterprise value of $1.6B.
Revenue in the twelve months to 30 June 2026: $69.7M. The latest quarter grew 30.0% year on year.
Net income over the same four quarters: −$107.2M, a −153.8% net margin.
Diluted earnings per share, trailing twelve months: $−1.09.
Free cash flow in the twelve months to 30 June 2026: −$101.0M.
Trailing P/E: −18.8×; forward P/E: −18.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Personalis, Inc. employs 259 people — $269K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Personalis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Personalis reported a second-quarter loss of $0.30 per share, wider than the Zacks Consensus Estimate of a $0.25 loss and worse than the $0.23 loss a year prior. The headline indicates revenue topped estimates.
Why it matters — PSNL watchers track how the company's quarterly results compare with consensus estimates, and this quarter's loss came in wider than expected.
Personalis reported its second quarter 2026 financial results and highlighted recent operational achievements, including receiving Medicare coverage approval for NeXT Personal for immunotherapy monitoring in late-stage solid tumor patients.
Why it matters — Medicare coverage for NeXT Personal opens a key reimbursement pathway for Personalis' core product in a large patient population, which could drive adoption and revenue.
A Monsey law firm, Wohl & Fruchter LLP, has launched an investigation into the fairness of Personalis's proposed sale to Tempus AI for $16.25 per share.
Why it matters — PSNL shareholders may face potential legal challenges or delays if the investigation finds the proposed sale price unfair.
Julie & Holleman LLP, a shareholder rights firm, announced it is investigating the proposed acquisition of Personalis, Inc. by Tempus AI, Inc., which is described as an existing Personalis shareholder and strategic partner.
Why it matters — The law firm's investigation signals that Personalis shareholders are examining potential claims related to the proposed sale to Tempus AI.
Halper Sadeh LLC is investigating whether Personalis, Inc. (PSNL) is obtaining a fair deal for its shareholders, noting that insiders may receive substantial financial benefits not available to ordinary shareholders.
Why it matters — An investigation into whether PSNL shareholders are being treated fairly compared to insiders could signal potential governance or deal-related concerns for investors.
The 5 Wall Street analysts covering Personalis, Inc. have a median 12-month price target of $16, with estimates ranging from $13 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Personalis, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Personalis, Inc. 41 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Personalis, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies -3.4% from the last close, and Ticker Nerd's factor model ranks Personalis, Inc. 41 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Personalis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PSNL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $16 over the next 12 months.
Personalis, Inc. returned +247.0% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Personalis Inc. is a biotechnology company focused on advanced cancer genomics and precision oncology.
The most recent item we track (Zacks Investment Research, 4 Aug 2026): "Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates". Personalis reported a second-quarter loss of $0.30 per share, wider than the Zacks Consensus Estimate of a $0.25 loss and worse than the $0.23 loss a year prior. The headline indicates revenue topped estimates.
Personalis Inc. is a biotechnology company focused on advanced cancer genomics and precision oncology. Personalis develops and markets genomic tests and sequencing services that help healthcare providers, pharmaceutical companies, biopharma partners, universities, and government organizations analyze tumor and immune-system signals. Its current offerings include liquid biopsy and molecular profiling solutions designed to detect minimal residual disease, monitor recurrence, and support therapy selection, along with sequencing and data analysis services for population-scale research programs. The company also provides platforms and assays used in immuno-oncology and personalized cancer vaccine development. Personalis serves customers primarily in the United States and Europe, with additional international reach through research and clinical applications. Headquartered in Fremont, California, Personalis plays an important role in translating complex genomic data into actionable insights for cancer research and patient management.
CEO Mr. Christopher M. Hall · 259 employees · United States · https://www.personalis.com
